Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Survivin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    18 result(s) found for: Survivin. Displaying page 1 of 1.
    EudraCT Number: 2010-020233-56 Sponsor Protocol Number: DC-006 Start Date*: 2011-03-24
    Sponsor Name:Oslo University Hospital
    Full Title: PHASE I/II TRIAL OF VACCINE THERAPY IN RELAPSED AND PLATINUM RESISTANT EPITHELIAL OVARIAN CANCER PATIENTS USING AUTOLOGOUS DENDRITIC CELLS LOADED WITH AMPLIFIED OVARIAN CANCER STEM CELL mRNA, hTE...
    Medical condition: Relapsed and platinum resistant epithelial ovarian carcinoma patients that have received one line of non-platinum chemotherapy in resistance disease setting.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-006619-64 Sponsor Protocol Number: 2006SG005 Start Date*: 2007-07-04
    Sponsor Name:University Hospital of South Manchester NHS Foundation Trust [...]
    1. University Hospital of South Manchester NHS Foundation Trust
    2. University of Manchester
    Full Title: Randomised Controlled Trial of Lapatinib (A Her1/2 Tyrosine Kinase Inhibitor) on Epithelial Proliferation and Apoptosis in Ductal Cancer in Situ.
    Medical condition: Women with a core biopsy diagnosis of histologically proven Her2 positive DCIS (or DCIS and invasive cancer). Women undergoing re-excision of DCIS will be eligible provided residual DCIS is presen...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065430 HER-2 positive breast cancer LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006253-41 Sponsor Protocol Number: DC-004 Start Date*: 2012-01-05
    Sponsor Name:The Norwegian Radium Hospital, Oslo University Hospital
    Full Title: Phase I/II trial for vaccine therapy with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion in patients with metastatic malignant melanoma
    Medical condition: Malignant melanoma stage IV M1c or better
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018770-20 Sponsor Protocol Number: DC-005 Start Date*: 2010-05-21
    Sponsor Name:Oslo University Hospital
    Full Title: Phase I/II trial of vaccine therapy in curative resected prostate cancer patients using autologous dendritic cells loaded with mRNA from primary prostate cancer tissue, hTERT and surviving.
    Medical condition: Prostatic cancer patients who have received curative surgery.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017798-39 Sponsor Protocol Number: PROVAX study Start Date*: 2010-07-08
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: An open label, Phase II study of vaccination with Survivin peptides emulsified in Montanide ISA 51VG after IMP 321 injection in prostate carcinoma patients with biochemical failure (PROVAX study)
    Medical condition: Prostate cancer, biochemical failure after all potentially curative standard local therapies (radiotherapy, brachytherapy and surgery) or biochemical progression while patients have castrated level...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10001200 Adenocarcinoma of the prostate stage I LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-005387-25 Sponsor Protocol Number: noprofit1616 Start Date*: 2016-05-05
    Sponsor Name:Sapienza, University of Rome
    Full Title: Phase 2a Study of an Immunotherapeutic Vaccine, DPX-Survivac, Alone or with Low dose Cyclophosphamide in Primary Glioblastoma Patients Receiving Standard of Care Therapy
    Medical condition: Glioblastoma is the most common primary brain tumour in humans with the most severe prognosis. Standard treatments consist primarily of surgery in order to debulk thetumoral mass, as well as radioc...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004865 10045172 Tumour vaccine therapies HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004467-31 Sponsor Protocol Number: DECENDO Start Date*: 2019-04-05
    Sponsor Name:
    Full Title: An exploratory study: Dendritic cells for immunotherapy of metastatic endometrial cancer patients
    Medical condition: metastatic endometrial cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-017591-24 Sponsor Protocol Number: H8Z-MC-JACW Start Date*: Information not available in EudraCT
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized Phase 2 Study of LY2181308 in Combination with Docetaxel versus Docetaxel in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer who Were Previously Treated with Fi...
    Medical condition: Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-004577-91 Sponsor Protocol Number: MM1120 Start Date*: 2011-12-20
    Sponsor Name:Center for Cancer ImmunTerapi CCIT, Hæmatologisk Afd. 54P4
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027150 Melanoma malignant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-002279-16 Sponsor Protocol Number: EOGBM1-18 Start Date*: 2020-01-02
    Sponsor Name:Enterome
    Full Title: A MulticenteR, Open-Label, First-in-Human, PhaSe Ib/IIa Trial of EO2401, a Novel Multipeptide Therapeutic VAccine, with and without PD-1 Check Point Inhibitor, FoLlowing Standard Treatment in PatIe...
    Medical condition: Progressive or recurrent Glioblastoma (PG)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-005057-36 Sponsor Protocol Number: GLG-801-07 Start Date*: 2018-05-17
    Sponsor Name:GLG Pharma S.A.
    Full Title: A Phase I/II Open-Label Study to Evaluate the Safety, Tolerability and Recommended Phase II Dose (RP2D) of GLG-801 in patients with Advanced Solid Tumors (Phase I); and safety, tolerability and ant...
    Medical condition: Metastatic triple-negative breast cancer Breast cancer, prostate cancer, ovarian cancer, head and neck cancer, NSCLC, colorectal cancer, gastric cancer, esophageal cancer, bladder cancer, renal ce...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010030 Colorectal cancer recurrent PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017761 Gastric cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005005 Bladder cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038390 Renal cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066600 Melanoma recurrent PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001174-81 Sponsor Protocol Number: D07-1 Start Date*: 2007-06-25
    Sponsor Name:GERCOR
    Full Title: RANDOMIZED MULTICENTER PHASE III STUDY IN PATIENTS WITH LOCALLY ADVANCED ADENOCARCINOMA OF THE PANCREAS: GEMCITABINE WITH OR WITHOUT CHEMORADIOTHERAPY AND WITH OR WITHOUT ERLOTINIB
    Medical condition: Patients with de novo locally advanced, histologically proven adenocarcinoma of the pancreas without distant metastases (stage III according to the UICC classification) and not considered for curat...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052747 Adenocarcinoma pancreas LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015738-31 Sponsor Protocol Number: 155-CL-034 Start Date*: 2009-12-15
    Sponsor Name:Astellas Pharma Global Development, Inc. (APGD)
    Full Title: A Phase II, Multicenter, Open-Label Study Of YM155 Plus Docetaxel in Subjects with Stage III (Unresectable) or Stage IV Melanoma
    Medical condition: Stage III (Unresectable) or Stage IV Melanoma.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10025670 Malignant melanoma stage III LLT
    12.0 10025671 Malignant melanoma stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-002893-23 Sponsor Protocol Number: H8Z-MC-JACS Start Date*: 2009-09-03
    Sponsor Name:Eli Lilly and Company
    Full Title: An Open Label Single Arm Phase 1b/2 Study with Pharmacokinetic Sampling to Evaluate LY2181308 in Patients with Advanced Hepatocellular Carcinoma
    Medical condition: Hepatocellular Carcinoma (HCC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-002793-91 Sponsor Protocol Number: Pervision Start Date*: Information not available in EudraCT
    Sponsor Name:University Hospital Tuebingen
    Full Title: Prospective phase I/II trial of an individualized peptide vaccine in pediatric and AYA patients with metastasized fusion-driven sarcomas following standard treatment
    Medical condition: The trial will include patients with so called "fusion-driven", metastatic sarcomas of the following types: - Ewing sarcoma, - alveolar rhabdomyosarcoma - or synovial sarcoma who are in first or s...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015560 Ewing's sarcoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065867 Alveolar rhabdomyosarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042863 Synovial sarcoma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-012439-14 Sponsor Protocol Number: 155-CL-036 Start Date*: 2010-01-26
    Sponsor Name:Astellas Pharma Global Development, Inc. (APGD)
    Full Title: A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects with HER2 Negative Metastatic Breast Cancer
    Medical condition: Adenocarcinoma of the breast that is HER2 negative.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) CZ (Completed) BE (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-010777-20 Sponsor Protocol Number: 155-CL-031 Start Date*: 2009-12-15
    Sponsor Name:Astellas Pharma Global Development, Inc. (APGD)
    Full Title: A Phase II, Multicenter, Open-Label Study Of YM155 Plus Rituximab In Previously Treated Subjects With CD20-Positive B Cell Non-Hodgkin’s Lymphoma Who Are Ineligible For Or Have Previously Received ...
    Medical condition: CD20-positive primary or transformed diffuse large B cell lymphoma (DLBCL), grade 3 follicular lymphoma (FL) and mantle cell lymphoma (MCL).
    Disease: Version SOC Term Classification Code Term Level
    12.0 10029592 Non-Hodgkin's lymphomas NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004907-37 Sponsor Protocol Number: H8Z-MC-JACR Start Date*: 2008-02-08
    Sponsor Name:Eli Lilly and Company limited
    Full Title: A randomized phase 2 study of LY2181308 in combination with docetaxel versus docetaxel in hormone refractory prostate cancer
    Medical condition: Hormone Refractory Prostate Cancer (HRPC)
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 18:02:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA